Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10

BACKGROUND: PARP inhibitors (PARPi) have revolutionized the management of advanced ovarian carcinoma, and were investigated as forefront treatment in recurrent disease. The objective was to explore if mathematical modeling of the early longitudinal CA-125 kinetics could be used as a pragmatic indica...

Descripción completa

Detalles Bibliográficos
Autores principales: Colomban, Olivier, Swisher, Elizabeth M., Kristeleit, Rebecca, McNeish, Iain, Shapira-Frommer, Ronnie, Goble, Sandra, Lin, Kevin K., Maloney, Lara, Freyer, Gilles, You, Benoit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972491/
https://www.ncbi.nlm.nih.gov/pubmed/36801617
http://dx.doi.org/10.1016/j.ebiom.2023.104477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972491/
https://www.ncbi.nlm.nih.gov/pubmed/36801617
http://dx.doi.org/10.1016/j.ebiom.2023.104477

Ejemplares similares